Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium®, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate
- 1 January 1994
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 21 (6) , 1075-1079
- https://doi.org/10.1016/s0168-8278(05)80620-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Stereoselective disposition of hexobarbital and its metabolitesPharmacogenetics, 1994
- Role of Cytochromes P45O in Drug Metabolism and HepatotoxicitySeminars in Liver Disease, 1990
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989
- 8 Acute and chronic drug-induced hepatitisBailliere's Clinical Gastroenterology, 1988
- A proposed mechanism for chlorpromazine jaundice — defective hepatic sulphoxidation combined with rapid hydroxylationJournal of Hepatology, 1988
- Genetically determined polymorphisms in drug oxidationHepatology, 1986
- Impaired oxidation of debrisoquine in patients with perhexiline liver injury.Gut, 1984
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Inherited Defects of Hepatic Drug MetabolismSeminars in Liver Disease, 1983
- Carbon Tetrachloride Hepatotoxicity: An Example of Lethal CleavageCRC Critical Reviews in Toxicology, 1973